Home » Stocks » BCEL

Atreca, Inc. (BCEL)

Stock Price: $15.30 USD -0.17 (-1.10%)
Updated Jan 26, 2021 4:00 PM EST - Market closed
Pre-market: $15.02 -0.28 (-1.83%) Jan 27, 8:04 AM
Market Cap 561.61M
Revenue (ttm) n/a
Net Income (ttm) -83.44M
Shares Out 34.72M
EPS (ttm) -6.36
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 26
Last Price $15.30
Previous Close $15.47
Change ($) -0.17
Change (%) -1.10%
Day's Open 15.63
Day's Range 15.20 - 16.08
Day's Volume 184,928
52-Week Range 11.40 - 27.28

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 2 months ago

SOUTH SAN FRANCISCO, Calif., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated t...

GlobeNewsWire - 2 months ago

SOUTH SAN FRANCISCO, Calif., Nov. 06, 2020 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a biotechnology company focused on developing novel therapeutics generated through a unique...

GlobeNewsWire - 3 months ago

SOUTH SAN FRANCISCO, Calif., Oct. 14, 2020 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated t...

Zacks Investment Research - 3 months ago

Atreca, Inc. (BCEL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

GlobeNewsWire - 4 months ago

SOUTH SAN FRANCISCO, Calif., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a biotechnology company focused on developing novel therapeutics generated through a uni...

Zacks Investment Research - 4 months ago

Atreca, Inc. (BCEL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

GlobeNewsWire - 5 months ago

SOUTH SAN FRANCISCO, Calif., Aug. 12, 2020 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated...

GlobeNewsWire - 5 months ago

SOUTH SAN FRANCISCO, Calif., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated...

GlobeNewsWire - 6 months ago

SOUTH SAN FRANCISCO, Calif., July 16, 2020 (GLOBE NEWSWIRE) -- Atreca, Inc. (Nasdaq: BCEL), a biopharmaceutical company utilizing its differentiated platform to discover and develop novel an...

GlobeNewsWire - 6 months ago

REDWOOD CITY, Calif., July 15, 2020 (GLOBE NEWSWIRE) -- Atreca, Inc. (Nasdaq: BCEL), a biopharmaceutical company utilizing its differentiated platform to discover and develop novel antibody-...

Zacks Investment Research - 6 months ago

Atreca, Inc. (BCEL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects.

GlobeNewsWire - 6 months ago

SOUTH SAN FRANCISCO, Calif. and MONROVIA, Calif., July 08, 2020 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel t...

GlobeNewsWire - 7 months ago

SOUTH SAN FRANCISCO, Calif., June 11, 2020 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated...

GlobeNewsWire - 8 months ago

SOUTH SAN FRANCISCO, Calif., May 21, 2020 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a biotechnology company focused on developing novel therapeutics generated through a uniqu...

GlobeNewsWire - 8 months ago

SOUTH SAN FRANCISCO, Calif., May 14, 2020 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated ...

The Motley Fool - 9 months ago

These three clinical-stage biotechs are all bargains after last month's marketwide downturn.

Other stocks mentioned: ADAP, CRSP
The Motley Fool - 10 months ago

The coronavirus induced sell-off has created a number of attractive buying opportunities.

Other stocks mentioned: ABBV, AGEN, APHA, BCYC, BMY, CPRX, CRNX, FOLD, GWPH, OGI, PFE, RCUS, SRPT
The Motley Fool - 11 months ago

These relative newcomers to the landscape of publicly-traded biotech stocks could be big winners for early shareholders.

Other stocks mentioned: CRNX
GlobeNewsWire - 11 months ago

SOUTH SAN FRANCISCO, Calif., Feb. 13, 2020 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a biotechnology company focused on developing novel therapeutics generated through a uniq...

GlobeNewsWire - 11 months ago

SOUTH SAN FRANCISCO, Calif., Feb. 05, 2020 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a biotechnology company focused on the development of novel cancer therapeutics generated...

Seeking Alpha - 1 year ago

Atreca's FDA Clearance Of Phase 1 Study Using ATRC-101 Brings It Into Unchartered Territory

GlobeNewsWire - 1 year ago

First IND clearance of a clinical candidate derived from Atreca’s differentiated drug discovery platform

GlobeNewsWire - 1 year ago

REDWOOD CITY, Calif., Aug. 26, 2019 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a biotechnology company focused on developing novel therapeutics based on a deep understanding o...

Benzinga - 1 year ago

The oncology drug development space holds “tremendous scarcity value for novel targets," and Atreca Inc’s (NASDAQ: BCEL) stock offers an investment opportunity at an attractive valuation, acco...

Benzinga - 1 year ago

Atreca, Inc. shares opened for trade Thursday morning at $19.90. The IPO of 7.35 million shares was priced at $17.

About BCEL

Atreca, a biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody in clinical development with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients. It has a strategic research collaboration with ... [Read more...]

Industry
Biotechnology
IPO Date
Jun 20, 2019
CEO
John Orwin
Employees
128
Stock Exchange
NASDAQ
Ticker Symbol
BCEL
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 9 analysts, the average rating for Atreca stock is "Strong Buy." The 12-month stock price forecast is 29.75, which is an increase of 94.44% from the latest price.

Price Target
$29.75
(94.44% upside)
Analyst Consensus: Strong Buy